Ian Tomlinson

Dr. Ian Tomlinson has over 30 years of experience in the life sciences sector from academic research to biotech startups to big pharma. He co-founded Domantis Limited with Nobel Laureate Sir Gregory Winter, which was acquired by GSK for $450 million. He then served as senior vice president, head of worldwide business development and head of biopharmaceuticals R&D at GSK, where he led an ambitious strategy to grow GSK’s pipeline of clinical-stage biopharmaceuticals from under 10% in 2008 to over 50% by 2016. Following his departure from GSK, he chaired the Stevenage Bioscience Catalyst, the UK’s first open innovation biomedical campus and was founding chair of Apollo Therapeutics. He is also chair of Start Codon. Ian spent 11 years at the MRC Laboratory of Molecular Biology, where he worked on antibody genes, antibody structure and various antibody technologies prior to starting his career in industry. He graduated from Trinity College, Cambridge, UK.